Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Swixx BioPharma - LARVOL DELTA

Acute and delayed mogamulizumab-associated rash with multiple pathologic subtypes in a patient with folliculotropic mycosis fungoides (AAD 2026) - "A 68-year-old man with relapsed and refractory FMF started mogamulizumab after failing NBUVB, methotrexate, interferon, prednisone, brentuximab, and bexarotene treatment. However, our patient has consistent B0 blood involvement. Future studies should assess MAR-associated long-term prognosis in FMF."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Psoriasiform Mycosis Fungoides: Report of Diagnostic Delays in Skin of Color and Challenges in Treating Advanced CTCL (AAD 2026) - "Despite multiple skin-directed and systemic therapies, including photopheresis, methotrexate, interferon alpha, and mogamulizumab, the disease progressed. Prognostic factors such as clinical stage, plaque disease, and serum lactate dehydrogenase should guide management. Increased awareness of MF variants in skin of color is needed to reduce disparities and improve outcomes."

Metastases • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • T Cell Non-Hodgkin Lymphoma

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. (PubMed, J Eur Acad Dermatol Venereol) - "Dupilumab may unmask or exacerbate CTCL, particularly MF and SS. The consensus-based recommendations offer practical guidance for the safe management of patients."

Journal • Review • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan (ICKSH 2026) - "For patients with major subtypes of peripheral T -cell lymphoma (PTCL), including PTCL not otherwise specified, angioimmunoblastic T -cell lymphoma (AITL), and anaplastic large cell lymphoma, the 2024 Japanese Society of Hematology (JSH) guidelines recommend the use of brentuximab vedotin (BV) -CHP for CD30 -positive tumors and CHOP -like regimens for CD30 -negative tumors as the first -line treatment...For patients with relapsed /refractory T-cell and NK/T -cell lymphoma, many therapeutic drugs (mogamulizumab, BV , pralatrexate, forodesine, romidepsin, alectinib, denileukin diftitox, tucidinostat, darinaparsin, and valemetostat) are approved and available in Japan...However, among immune checkpoint inhibitors, only atezolizumab was approved for the treatment of ENKL in 2025, and little experience is available with its use. Patients with ENKL in Japan account for less than 1% of all lymphoma patients, which is as low as in Western countries. To fill these gaps, an..."

Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Mogamulizumab-Associated Cryoglobulinemkc Glomeulomephritis : A Case Report (NKF-SCM 2026) - "Mogamulizumab was stopped, and the patient was treated with pulse steroids followed by prednisone and rituximab. Recognition is critical, as prompt immunosuppression and drug discontinuation may improve outcomes CONCLUSION This appears to be the first case of mogamulizumab-associated cryoglobulinemic GN. Given the timing and lack of other causes, a drug-induced immune mechanism is likely; clinicians should watch for renal immune toxicity"

Case report • Clinical • Complement-mediated Rare Disorders • Cutaneous T-cell Lymphoma • Glomerulonephritis • Hematological Malignancies • Immunology • Infectious Disease • Lupus Nephritis • Lymphoma • Nephrology • Renal Disease • CCR4

Mogamulizumab-induced drug eruption during multiagent chemotherapy: A possible CD8+ T cell-mediated mechanism. (PubMed, JAAD Case Rep) - No abstract available

Journal

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma. (PubMed, Blood) - "Moga-CHOP is now considered a preferable first-line treatment for these patients. Clinical Trial Identifier: jRCTs041180130."

IO biomarker • Journal • P2 data • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CCR4

BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides. (PubMed, Front Cell Infect Microbiol) - "This is the first documented case of BKPyV-associated PML in a Mogamulizumab-treated patient. These findings highlight intra-host heterogeneity at the protein level, possibly reflecting compartment-specific viral evolution, and underscore the need for vigilant BKPyV and JCPyV monitoring during Mogamulizumab treatment."

Journal • CNS Disorders • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Mycosis Fungoides • Oncology • Psychiatry • Rare Diseases • Renal Disease • CCR4

Mogamulizumab-Associated Kaposi Sarcoma in 2 Patients With Primary Cutaneous T-Cell Lymphomas. (PubMed, JAMA Dermatol) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Hematological Malignancies • Kaposi Sarcoma • Lymphoma • Oncology • Sarcoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: John Reneau | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Adult T-Cell Leukemia-Lymphoma • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study. (PubMed, Front Oncol) - "The observed median overall survival (OS) was 11.5 months, with 1 reported death due to septic shock in a patient who underwent salvage allo-HSCT after mogamulizumab failure. The results of this study reaffirm the efficacy of Mogamulizumab therapy for patients with Mycosis Fungoides and Sézary Syndrome in a real-world setting, which involves treatment decisions that must often consider patient heterogeneity, comorbidities, and prior lines of therapy."

Journal • Retrospective data • Bone Marrow Transplantation • Breast Cancer • Cutaneous T-cell Lymphoma • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Septic Shock • Sezary Syndrome • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CCR4

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial. (PubMed, Cancers (Basel)) - P2 | "The remaining patient experienced stress cardiomyopathy during the third cycle and was taken off the study. In striking difference to the observation in solid malignancies, the combination of mogamulizumab with pembrolizumab was associated with low tolerability and suspected hyper-progression in patients with lymphoma."

Journal • P1 data • B Cell Lymphoma • Cardiomyopathy • Cardiovascular • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma

A historical review of mycosis fungoides: from Alibert to mogamulizumab. (PubMed, Skin Health Dis) - "Developments in immunohistochemistry for the T-cell receptor gene in the 1990s improved the diagnosis of CTCL; however, diagnosis is still challenging. Advanced MF therapies have evolved from cytotoxic chemotherapy to novel monoclonal antibodies such as mogamulizumab, targeting proteins on T-cell lymphoma cells."

Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 (ASH 2022) - P3 | "Approximately half (34 of 69; 49.3%) of patients had prior exposure to 1 or more FDA-approved targeted therapeutics: romidepsin, brentuximab, or mogamulizumab. In study 302, E7777 at a dose of 9 mcg/kg/day demonstrated clinical efficacy and clinically meaningful benefit in heavily pre-treated patients with relapsed/refractory CTCL. The ORR of 36.2% per IRC (42.3% by investigator assessment) showed that a substantial proportion of these heavily pretreated patients experienced clinical benefit after E7777 treatment similar to ONTAK. The observed tumor responses were rapid, durable, and deep."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Fatigue • Hematological Malignancies • Hepatology • Infectious Disease • Lymphoma • Oncology • Pruritus • T Cell Non-Hodgkin Lymphoma • IL2

Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets. (PubMed, Curr Issues Mol Biol) - "Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers."

Biomarker • IO biomarker • Journal • Review • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CCL19 • CCL2 • CCL21 • CCL22 • CCL27 • CCR10 • CCR2 • CCR4 • CCR6 • CCR7 • CCR8 • CD4 • CXCL12 • CXCR3 • CXCR4 • CXCR5

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. (PubMed, Cancer) - P1 | "KHK2455 + mogamulizumab was safe and well tolerated with manageable toxicities, and resulted in dose-dependent suppression of IDO1 activity; signals of antitumor activity were observed."

Journal • Monotherapy • P1 data • Brain Cancer • Esophageal Cancer • Glioblastoma • Oncology • Solid Tumor • CCR4

Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study (Front Oncol) - "Of the 12 patients treated, 8 had MF and 4 had SS. The median follow-up time was 29.9 months (range 2.8–68.6 months). Four patients discontinued mogamulizumab: 3 due to disease progression and 1 due to the development of breast cancer. Adverse events included MAR in 4 patients (33%) and colitis in 1 patient (6%). The observed median PFS after mogamulizumab therapy was 5.4 months, and the observed ORR was 50%. For all 12 patients, the median time to response (TTR) was 129 days."

Retrospective data • Mycosis Fungoides • Sezary Syndrome

Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. (PubMed, Haematologica) - P2 | "Investigator choice chemotherapy did not result in tumor response in this trial; however, mogamulizumab treatment resulted in 11% confirmed overall response rate, with a tolerable safety profile. This trial was registered at www.clinicaltrials.gov as NCT01626664."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia

Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial. (ASCO 2025) - P2 | "The long term follow-up data from TELLOMAK study in a R/R SS population previously treated with 2 or more prior systemic therapies including mogamulizumab, confirm that lacutamab shows promising clinical activity with ORR 42.9% (95% CI 31.4-55.1) and median duration of response of 25.6 months (11.0, NE) and an overall favourable safety profile. These data support the further development of lacutamab in an effort to bring improved treatments to patients with SS."

Clinical • P2 data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Sezary Syndrome • KIR3DL2

An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. (PubMed, Blood) - P2 | "Twenty-five patients (median age, 69.0) with a median of 3 prior lines of therapy were enrolled; 24 had prior mogamulizumab treatment. Grade ≥3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL."

Journal • P2 data • Adult T-Cell Leukemia-Lymphoma • Alopecia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • EZH2

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL) (ASH 2022) - "In the Phase III MAVORIC trial comparing mogamulizumab to vorinostat, mogamulizumab-associated rash (MAR) was reported in 25% of patients (pts) and was more common in responders than in non-responders. The development of MAR in patients with CTCL is associated with higher rates of CR and ORR and significantly longer PFS and OS. CR/PR response in blood were associated with improved PFS. Additionally, 40% of patients who developed MAR and discontinued mogamulizumab had ongoing responses without additional systemic therapy."

IO biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CCR4

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial (ASH 2023) - P2 | "Conclusion In this SS cohort from the TELLOMAK study, our data confirm that lacutamab monotherapy shows promising clinical activity in a R/R population previously treated with 2 or more prior systemic therapies including mogamulizumab, and an overall favourable safety profile. Continued evaluation of this new targeted treatment option for patients with SS is warranted."

Clinical • P2 data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pruritus • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • KIR3DL2

Sézary syndrome presenting as vitiligo-like leukoderma with response and repigmentation to mogamulizumab and extracorporeal photopheresis. (PubMed, JAAD Case Rep) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • Vitiligo

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas (clinicaltrials.gov) - P2 | N=23 | Recruiting | Sponsor: University of Michigan Rogel Cancer Center | Trial completion date: Dec 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report. (PubMed, Ther Adv Hematol) - "The patient achieved a partial response with methotrexate but discontinued after ~12 months due to elevated transaminases. Following treatment with bexarotene then gemcitabine, CHOP chemotherapy was initiated in December 2019, but, after a period of partial skin response, the patient relapsed with progression of skin lesions...Disease progression in the skin occurred in December 2020; mogamulizumab was continued, and the patient achieved remission with the addition of etoposide and prednisone in August 2021...In October 2022, the patient was diagnosed with large cell CD30+ transformation, and the therapeutic approach was changed to extracorporeal photopheresis, brentuximab vedotin, and topical steroids. The patient died in February 2023 due to sepsis. Our experience adds to the limited evidence that mogamulizumab may be continued in combination with etoposide following disease progression in patients with MF with blood involvement; however, more research is needed on the..."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Pain • Septic Shock • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • TNFRSF8